drugset / Trial / NCT03400943

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943

Phase 3 Terminated 93 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study was to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Timeline

Start
2018-01-17
Primary completion
2019-06-09
Completion
2022-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg

Indications